Company Overview - TD SYNNEX Corporation is a significant player in the business process services sector, distributing a variety of products including PC systems, mobile phones, IT systems, and consumer electronics. The company also offers systems design, logistics, cloud services, and marketing services to resellers, system integrators, and retailers, positioning itself as a key player in the technology distribution industry [1] Price Target Trends - The consensus price target for TD SYNNEX has shown an upward trend over the past year, increasing from $148.22 a year ago to $155.6 in the last quarter, and further to $173 in the past month, indicating growing optimism among analysts regarding the company's stock performance [2][6] Financial Performance - In the second quarter, TD SYNNEX reported strong financial results, surpassing guidance with significant revenue growth, improved profit margins, and impressive cash generation. The company's business model, focusing on scale and efficient management of working capital, supports its high-quality economic framework [3][6] Upcoming Earnings Report - The upcoming third-quarter earnings report is expected to reflect higher earnings for TD SYNNEX, with the stock having already increased by 5.8% since the last earnings report 30 days ago. Despite a lower price target of $130 from analyst Matthew Sheerin, the overall sentiment remains positive, with a valuation analysis suggesting a fair value between $170 and $175 [4][5] Investment Case - The strong financial performance of TD SYNNEX, along with a trailing free cash flow yield of 6% and steady dividend growth, strengthens the investment case for the company [5]

Core Viewpoint - Amneal Pharmaceuticals (AMRX) has seen a 22.1% increase in share price over the past four weeks, closing at $9.56, with a potential upside of 25.5% based on Wall Street analysts' mean price target of $12 [1][4]. Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $0.82, indicating variability among analysts [2]. - The lowest price target of $11.00 suggests a 15.1% increase, while the highest target of $13.00 indicates a potential surge of 36% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price direction [9]. Earnings Estimates and Market Sentiment - Analysts are optimistic about AMRX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price increases [11]. - Over the last 30 days, three earnings estimates have been revised upward, leading to a 7.8% increase in the Zacks Consensus Estimate [12]. - AMRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][10]. - Price targets can often be inflated due to business incentives, leading to overly optimistic projections [8].

Core Viewpoint - Thryv Holdings, Inc. (THRY) has seen a 16% increase in share price over the past four weeks, closing at $13.8, with analysts suggesting a potential upside of 55.1% based on a mean price target of $21.4 [1] Price Targets and Analyst Consensus - The average price target for THRY is based on five short-term estimates, ranging from a low of $16.00 to a high of $26.00, with a standard deviation of $4.1, indicating variability among analysts [2] - The lowest estimate suggests a 15.9% increase from the current price, while the highest estimate indicates an 88.4% upside [2] - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7][10] Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding THRY's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] - Over the last 30 days, one earnings estimate has increased, leading to a 27% rise in the Zacks Consensus Estimate for the current year [12] - THRY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of THRY's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Group 1 - Aligos Therapeutics, Inc. (ALGS) closed at $8.77, with a 1.5% gain over the past four weeks, and a mean price target of $95 suggests a potential upside of 983.2% [1] - The mean estimate includes three short-term price targets with a standard deviation of $69.46, indicating variability; the lowest estimate of $50.00 suggests a 470.1% increase, while the highest target of $175.00 indicates a potential surge of 1895.4% [2] - Analysts agree that ALGS is expected to report better earnings than previously estimated, which strengthens the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for ALGS has increased by 14.9% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - ALGS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While the consensus price target may not be a reliable indicator of the extent of gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Kiniksa Pharmaceuticals International, plc (KNSA) has seen a 15% increase in share price over the past four weeks, closing at $33.38, with analysts suggesting a potential upside of 26.7% based on a mean price target of $42.29 [1][12]. Price Targets and Analyst Consensus - The average price target for KNSA is derived from seven short-term estimates, ranging from a low of $32.00 to a high of $55.00, with a standard deviation of $8.96, indicating variability in analyst predictions [2]. - The lowest estimate suggests a decline of 4.1%, while the highest indicates a potential upside of 64.8% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding KNSA's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11]. - The Zacks Consensus Estimate for the current year has increased by 39.2% over the past month, with three estimates revised upward and no negative revisions [12]. - KNSA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Price Movement Implications - While consensus price targets may not reliably predict the extent of KNSA's gains, the implied direction of price movement appears to be a useful guide for investors [14].

Group 1 - El Pollo Loco Holdings (LOCO) shares have increased by 1% over the past four weeks, closing at $10.69, with a mean price target of $13.75 indicating a potential upside of 28.6% [1] - The mean estimate consists of four short-term price targets with a standard deviation of $2.99, where the lowest estimate is $11.00 (2.9% increase) and the highest is $18.00 (68.4% increase) [2] - Analysts show strong agreement on LOCO's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for LOCO has risen by 2.7% over the past month, with two estimates increasing and no negative revisions [12] - LOCO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide guidance on the direction of price movement [14]

Core Viewpoint - Enerflex (EFXT) has shown a significant price increase of 13.9% over the past four weeks, with a mean price target of $11.81 indicating a potential upside of 28.8% from its current price of $9.17 [1] Price Targets and Analyst Consensus - The average price target consists of eight estimates ranging from a low of $9.25 to a high of $13.81, with a standard deviation of $1.58, indicating variability among analysts [2] - The lowest estimate suggests a modest increase of 0.9%, while the highest estimate indicates a substantial upside of 50.6% [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement direction, although it does not guarantee reaching the average target [9] Earnings Estimates and Analyst Optimism - Analysts exhibit strong agreement in revising earnings estimates higher for EFXT, which correlates with potential stock price increases [11] - Over the past 30 days, two earnings estimates have increased while one has decreased, leading to a 37.8% rise in the Zacks Consensus Estimate for the current year [12] - EFXT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a solid potential upside [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research indicates they often do not accurately predict stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - Soleno Therapeutics, Inc. (SLNO) shares have increased by 1% over the past four weeks, closing at $82.35, with a mean price target of $117.88 indicating a potential upside of 43.2% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $13.62, where the lowest estimate is $100.00 (21.4% increase) and the highest is $145.00 (76.1% increase) [2] - Analysts show a strong consensus that SLNO will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for SLNO's current year earnings has risen by 56.7% over the past month, with five estimates increasing and no negative revisions [12] - SLNO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for near-term upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Core Viewpoint - Sky Harbour Group Corporation (SKYH) shows potential for significant upside, with a mean price target of $17.92 indicating a 73% increase from its current price of $10.36 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $4.8, suggesting variability in analyst predictions [2] - The lowest estimate of $14.00 indicates a 35.1% increase, while the highest estimate of $25.00 suggests a potential surge of 141.3% [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about SKYH's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, one estimate has increased, leading to a 9.8% rise in the Zacks Consensus Estimate [12] - SKYH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][7] - Price targets should be treated with skepticism, as they can mislead investors [10]

Group 1 - Rapt Therapeutics (RAPT) shares have increased by 34.2% over the past four weeks, closing at $10.8, with a mean price target of $24 indicating a potential upside of 122.2% [1] - The average price targets range from a low of $14.00 to a high of $31.00, with a standard deviation of $8.89, suggesting a variability in estimates; the lowest estimate indicates a 29.6% increase, while the highest points to a 187% upside [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 33.4% [4][12] Group 2 - RAPT currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - While price targets can be misleading, the direction implied by the consensus price target suggests a positive outlook for RAPT's stock [10][14]